(Q40688945)

22 September 2017

title

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study (English)

1 reference

22 September 2017

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Eva Havrdová

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Anna Belova

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Alla Goloborodko

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Anne Tisserant

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Andrew Wright

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Erik Wallstroem

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Hideki Garren

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Donald R Johns

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

3 May 2016

1 reference

22 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

1287-1295

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis

5 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Secukinumab in plaque psoriasis--results of two phase 3 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-016-8128-X

A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27142710

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00415-016-8128-X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27142710%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference